Funktionsmenü_neu

Hauptnavigation

Sub-Navigation
Klickpfad

Review of Sorafenib data at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 13 to May 17, 2005

Zurück zur Übersicht


Tuesday, May 17, 2005

Investor Conference Call ASCO Review 2005:

Audio On-demand
  

Press Releases

Bayer and Onyx Initiate Phase III Metastatic Melanoma Trial Administering Sorafenib (BAY 43-9006) in Combination with Chemotherapy

  PDF / 193 KB collectBayerNews_20050513_6287_en.pdf BayerNews_20050513_6287_en.pdf

Sorafenib (BAY 43-9006) Doubles Progression-Free Survival in Phase III Kidney Cancer Trial
Independent Assessment Shows Median Progression-Free Survival of 24 Weeks

  PDF / 196 KB collectBayerNews_20050514_6280_en.pdf BayerNews_20050514_6280_en.pdf

Bayer and Onyx Announce Access to Sorafenib (BAY 43-9006) for Individuals with Advanced Renal Cell Carcinoma
Treatment Protocol has been Reviewed by FDA

  PDF / 200 KB collectBayerNews_20050514_6297_en.pdf BayerNews_20050514_6297_en.pdf

Fact Sheets and Background Information

  

Sorafenib Clinical Program Overview

  PDF / 123 KB collectSorafenib_ClinicalProgramOverview.pdf Sorafenib_ClinicalProgramOverview

Sorafenib Fact Sheet

  PDF / 142 KB collectSorafenib_FactSheet.pdf Sorafenib FactSheet

Renal Cell Carcinoma Fact Sheet

  PDF / 117 KB collectRCC_FactSheet.pdf RCC FactSheet

Hepatocellular Carcinoma Fact Sheet

  PDF / 141 KB collectHCC_FactSheet.pdf HCC FactSheet

Melanoma Fact Sheet

  PDF / 122 KB collectMelanoma_FactSheet.pdf Events\Melanoma FactSheet

Sorafenib at ASCO 2005

  PDF / 122 KB collectSorafenib_at_ASCO2005.pdf Sorafenib_at_ASCO2005

Abstracts and Oral Presentations on Sorafenib at ASCO 2005

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: LBA4510)

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: 4544 )

A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) ( Abstract No: 5566)

Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients ( Abstract No: 7508)

Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma ( Abstract No: 3037)

A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) ( Abstract No: 3067)

Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma ( Abstract No: 3005)

Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: A prospective study ( Abstract No: 3069)

Useful Links:

ASCO Homepage: www.asco.org

Clinical trials information: www.clinicaltrials.gov

American Cancer Society: www.cancer.org

Information on renal cell cancer: www.KidneyCancer.org

Information on liver cancer: www.liverfoundation.org

Information on melanoma: www.melanomainternational.org

Information on cancer incidence, prevalence and mortality (GLOBOCAN): www-dep.iarc.fr

nach oben

You are leaving the Bayer AG website.

Bayer AG is not responsible for the information on the website to which you are linking.

Latest Reports and Handout